The stock will trade on the upcoming data update and pre-BLA meeting with the FDA in 4Q 2026, not on the quarterly financial results. Monitor for the data release on CR rates and durability from the LEGEND trial, as positive results could drive a significant re-rating ahead of the BLA submission.
Price Chart
Executive Summary
enGene reported Q3 2026 results with a net loss of $0.47 per share, which was a 17.5% beat vs the $-0.48 consensus, but the company remains a pre-revenue clinical-stage biotech. The key catalyst is the planned pre-BLA meeting with the FDA and initiation of a BLA filing for detalimogene in 4Q 2026, with a potential FDA approval decision in 2027. The filing is neutral as the financial results are immaterial for a pre-revenue company, and the clinical/regulatory milestones, while significant, are still forward-looking and binary in nature.
Key Financial Metrics
Key Facts
- Net loss of $32.5M for Q3 2026, or $0.47 per share, compared to $29.0M ($0.57 per share) in Q3 2025.
- Cash, cash equivalents, and marketable securities of $266.3M as of July 31, 2026.
- Pre-BLA meeting with the FDA and initiation of BLA filing for detalimogene planned for 4Q 2026.
- Data update on key regulatory endpoints from LEGEND's pivotal Cohort 1 planned for 4Q 2026.
- Detalimogene plus surfactant cohort safety run-in successfully cleared.
- Potential FDA approval decision for detalimogene and platform designation in 2027.
Financial Impact
Pre-revenue clinical-stage biotech; net loss of $32.5M in Q3 2026, cash burn rate of ~$11M/month based on cash balance of $266.3M.
Risk Factors
- Clinical trial failure or disappointing durability data from the LEGEND pivotal cohort.
- FDA delays or rejection of the BLA filing for detalimogene.
- Cash runway may be insufficient to fund operations to a potential approval in 2027 without additional financing.
- Competition from other NMIBC therapies, including those with surfactant-enhanced delivery.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-384380 |
| Document: engn-20260908.htm | 0001193125-26-384380 |
| Document: 0001193125-26-384380-index-headers.html | 0001193125-26-384380 |
| Document: 0001193125-26-384380-index.html | 0001193125-26-384380 |
| Document: 0001193125-26-384380.txt | 0001193125-26-384380 |
| 8-K Data (Synthetic) | 0001193125-26-384380 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 7w ago | 8-K | $1.92 | awaiting T+60 | — | $1.55 (−19.27%) |
Aug 11, 2026 11w ago | 8-K | $1.70 | awaiting T+60 | — | $1.55 (−8.82%) |
Jul 16, 2026 14w ago | 8-K | $1.92 $1.73 | ▼ −9.90% | ▼ −13.61% | $1.55 (−19.27%) |
Jun 15, 2026 19w ago | 8-K | $1.77 $1.85 | ▼ −4.52% | ▼ −3.52% | $1.55 (+12.43%) |
Mar 3, 2026 34w ago | EFFECT | $9.66 $1.72 | ▼ −82.19% | ▼ −92.51% | $1.55 (−83.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers